Clinical Trial Update: Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial comparing romiplostim to eltrombopag for thrombocytopenia in Wiskott-Aldrich Syndrome; efficacy and safety data not disclosed in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wiskott-aldrich Syndrome

Drugs mentioned

• Eltrombopag (eltrombopag)
• Romiplostim (romiplostim)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Wiskott-Aldrich Syndrome | Phase 2 | Status: UNKNOWN